Posted inAllergy & Immunology Gastroenterology news
Zetomipzomib Shows Promise in Difficult-to-Treat Autoimmune Hepatitis: Insights from the Phase 2a PORTOLA Study
The PORTOLA phase 2a trial evaluates zetomipzomib, a selective immunoproteasome inhibitor, demonstrating numerically improved biochemical remission and steroid-sparing effects in autoimmune hepatitis patients with inadequate response to standard treatments.
